Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Ionis Pharmaceuticals

DB:ISI
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ISI
DB
$7B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The last earnings update was 38 days ago. More info.


Add to Portfolio Compare Print
  • Ionis Pharmaceuticals has significant price volatility in the past 3 months.
ISI Share Price and Events
7 Day Returns
4.1%
DB:ISI
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-39.7%
DB:ISI
-7.4%
DE Biotechs
-14.2%
DE Market
ISI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ionis Pharmaceuticals (ISI) 4.1% -3.1% -20.5% -39.7% 24.5% -26.1%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • ISI underperformed the Biotechs industry which returned -7.4% over the past year.
  • ISI underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
ISI
Industry
5yr Volatility vs Market

ISI Value

 Is Ionis Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Ionis Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Ionis Pharmaceuticals.

DB:ISI Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 19 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:ISI
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (10.77%))
1.092
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.09
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.092 * 5.44%)
5.55%

Discounted Cash Flow Calculation for DB:ISI using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Ionis Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:ISI DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.55%)
2020 149.00 Analyst x5 141.16
2021 164.50 Analyst x6 147.65
2022 280.83 Analyst x6 238.82
2023 431.00 Analyst x6 347.25
2024 563.33 Analyst x6 430.00
2025 659.03 Est @ 16.99% 476.59
2026 736.63 Est @ 11.77% 504.69
2027 796.48 Est @ 8.13% 517.01
2028 840.85 Est @ 5.57% 517.10
2029 872.66 Est @ 3.78% 508.44
Present value of next 10 years cash flows $3,828.00
DB:ISI DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $872.66 × (1 + -0.39%) ÷ (5.55% – -0.39%)
$14,632.74
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $14,632.74 ÷ (1 + 5.55%)10
$8,525.58
DB:ISI Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $3,828.00 + $8,525.58
$12,353.58
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $12,353.58 / 139.22
$88.73
DB:ISI Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:ISI represents 0.86829x of NasdaqGS:IONS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86829x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 88.73 x 0.86829
€77.05
Value per share (EUR) From above. €77.05
Current discount Discount to share price of €45.59
= -1 x (€45.59 - €77.05) / €77.05
40.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Ionis Pharmaceuticals is available for.
Intrinsic value
41%
Share price is €45.59 vs Future cash flow value of €77.05
Current Discount Checks
For Ionis Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Ionis Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Ionis Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ionis Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ionis Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ISI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $2.12
NasdaqGS:IONS Share Price ** NasdaqGS (2020-04-08) in USD $52.5
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ionis Pharmaceuticals.

DB:ISI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:IONS Share Price ÷ EPS (both in USD)

= 52.5 ÷ 2.12

24.78x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ionis Pharmaceuticals is good value based on earnings compared to the Europe Biotechs industry average.
  • Ionis Pharmaceuticals is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Ionis Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:ISI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 24.78x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts
13.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

DB:ISI PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 24.78x ÷ 13.3%

1.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ionis Pharmaceuticals is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Ionis Pharmaceuticals's assets?
Raw Data
DB:ISI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $10.48
NasdaqGS:IONS Share Price * NasdaqGS (2020-04-08) in USD $52.5
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:ISI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:IONS Share Price ÷ Book Value per Share (both in USD)

= 52.5 ÷ 10.48

5.01x

* Primary Listing of Ionis Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ionis Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Ionis Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Ionis Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ISI Future Performance

 How is Ionis Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 19 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ionis Pharmaceuticals expected to grow at an attractive rate?
  • Ionis Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Ionis Pharmaceuticals's earnings growth is positive but not above the Germany market average.
  • Ionis Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:ISI Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:ISI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts 13.3%
DB:ISI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 19 Analysts 7.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ISI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ISI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 1,561 492 391 7
2023-12-31 1,304 349 234 8
2022-12-31 1,051 217 101 12
2021-12-31 902 116 29 17
2020-12-31 773 54 -23 19
2020-04-09
DB:ISI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 1,123 346 297
2019-09-30 821 183 433
2019-06-30 799 170 402
2019-03-31 752 697 366
2018-12-31 600 603 277
2018-09-30 575 508 -41
2018-06-30 548 563 -38
2018-03-31 543 65 9
2017-12-31 514 174 19
2017-09-30 507 127 42
2017-06-30 499 122 52
2017-03-31 426 86 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ionis Pharmaceuticals's earnings are expected to grow by 13.3% yearly, however this is not considered high growth (20% yearly).
  • Ionis Pharmaceuticals's revenue is expected to grow by 7.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ISI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below

All data from Ionis Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ISI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 2.52 6.25 0.30 6.00
2023-12-31 1.55 5.06 -0.66 7.00
2022-12-31 0.69 3.24 -0.99 11.00
2021-12-31 0.34 2.37 -1.10 18.00
2020-12-31 -0.11 0.72 -0.86 20.00
2020-04-09
DB:ISI Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 2.12
2019-09-30 3.11
2019-06-30 2.90
2019-03-31 2.70
2018-12-31 2.09
2018-09-30 -0.32
2018-06-30 -0.30
2018-03-31 0.07
2017-12-31 0.15
2017-09-30 0.34
2017-06-30 0.42
2017-03-31 -0.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Ionis Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Ionis Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ionis Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ISI Past Performance

  How has Ionis Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ionis Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ionis Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
  • Ionis Pharmaceuticals's 1-year earnings growth is less than its 5-year average (7.1% vs 67.3%)
  • Ionis Pharmaceuticals's earnings growth has not exceeded the Europe Biotechs industry average in the past year (7.1% vs 14.9%).
Earnings and Revenue History
Ionis Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ionis Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ISI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1,122.60 296.56 286.64
2019-09-30 821.03 432.80 269.43
2019-06-30 798.54 402.03 278.10
2019-03-31 752.47 365.62 269.19
2018-12-31 599.67 276.87 244.62
2018-09-30 575.35 -40.69 224.27
2018-06-30 548.27 -38.04 182.35
2018-03-31 542.80 8.62 138.46
2017-12-31 514.18 18.79 108.49
2017-09-30 506.74 42.19 80.82
2017-06-30 499.35 51.51 64.22
2017-03-31 425.55 -14.68 51.73
2016-12-31 372.78 -60.40 48.62
2016-09-30 237.84 -183.85 43.76
2016-06-30 176.04 -226.98 42.32
2016-03-31 257.99 -134.48 40.27
2015-12-31 283.70 -88.28 37.17
2015-09-30 316.99 14.21 30.82
2015-06-30 311.94 23.31 26.54
2015-03-31 248.58 -24.42 23.23
2014-12-31 214.16 -38.98 20.14
2014-09-30 171.55 -94.31 17.99
2014-06-30 151.07 -92.21 16.95
2014-03-31 132.09 -90.25 15.88
2013-12-31 147.29 -60.64 14.92
2013-09-30 124.91 -39.01 13.48
2013-06-30 112.93 -52.07 9.74

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Ionis Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Ionis Pharmaceuticals used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Ionis Pharmaceuticals has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Ionis Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ionis Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ISI Health

 How is Ionis Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ionis Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ionis Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ionis Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ionis Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ionis Pharmaceuticals Company Filings, last reported 3 months ago.

DB:ISI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,684.55 770.29 2,508.76
2019-09-30 1,497.97 656.60 2,221.44
2019-06-30 1,457.20 659.52 2,262.93
2019-03-31 1,387.42 650.12 2,255.93
2018-12-31 1,187.16 640.56 2,086.63
2018-09-30 840.14 638.62 1,958.99
2018-06-30 817.44 625.84 1,980.45
2018-03-31 387.10 614.42 1,035.30
2017-12-31 365.28 605.38 1,022.72
2017-09-30 397.67 597.65 1,010.81
2017-06-30 215.57 553.11 855.71
2017-03-31 201.81 523.51 860.28
2016-12-31 99.57 516.75 665.22
2016-09-30 139.64 422.95 697.23
2016-06-30 111.21 412.70 672.31
2016-03-31 158.16 406.65 723.51
2015-12-31 200.79 400.74 803.98
2015-09-30 245.41 399.98 830.79
2015-06-30 300.32 394.94 815.54
2015-03-31 275.85 390.42 788.50
2014-12-31 257.78 386.05 810.71
2014-09-30 344.77 163.14 640.43
2014-06-30 366.86 162.42 649.37
2014-03-31 374.10 161.84 697.78
2013-12-31 378.39 161.28 710.13
2013-09-30 401.45 159.74 737.73
2013-06-30 401.08 159.33 654.38
  • Ionis Pharmaceuticals's level of debt (45.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (149.7% vs 45.7% today).
  • Debt is well covered by operating cash flow (44.9%, greater than 20% of total debt).
  • Ionis Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Ionis Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ionis Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ISI Dividends

 What is Ionis Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ionis Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Ionis Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ionis Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ionis Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ISI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:ISI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 3.00
2021-12-31 0.00 4.00
2020-12-31 0.00 4.00
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ionis Pharmaceuticals has not reported any payouts.
  • Unable to verify if Ionis Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ionis Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ionis Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Ionis Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Ionis Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ionis Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ionis Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ISI Management

 What is the CEO of Ionis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Brett Monia
COMPENSATION $4,275,699
AGE 58
TENURE AS CEO 0.3 years
CEO Bio

Dr. Brett P. Monia, Ph.D., is a Founder of Ionis Pharmaceuticals, Inc. and has been its Chief Executive Officer since 2020. Dr. Monia is Chief Operating Officer of Ionis Pharmaceuticals, Inc. since January 15, 2018 and served as its Senior Vice President of Drug Discovery & Corporate Development since January 2012. Dr. Monia has been a Director of Ionis Pharmaceuticals, Inc. since March 25, 2019. Dr. Monia served as Senior Vice President of Translational Medicine from 2018 to January 2020 and served as its Senior Vice President of Antisense Drug Discovery since 2018 until 2018. Dr. Monia served as Senior Vice President of Antisense Drug Discovery at Ionis Pharmaceuticals (Isis Pharmaceuticals, Inc.) since January 2012. Dr. Monia is a founding member of Isis and Senior Vice President of Antisense Drug Discovery. Dr. Monia is also the Franchise Leader for Programs in Oncology and Rare Genetic Diseases at Isis Pharmaceuticals. He is responsible for establishing strategic directions for preclinical drug discovery research focused on RNA-directed therapeutic platforms, establishment and supervision of early clinical development strategies through clinical proof-of-concept and coordinating research activities with clinical investigators, consultants and with corporate partners. His contributions include research into the medicinal chemistry and mechanisms of action of oligonucleotide-based drugs in cell culture and in animals and in the establishment of numerous preclinical and clinical programs in various therapeutic areas, including oncology, metabolic disease, inflammation, cardiovascular disease and rare diseases. Programs under Dr. Monia's direct supervision have resulted in the clinical development of more than twenty antisense-based drugs to date, covering areas as diverse as cancer, type 2 diabetes, cardiovascular disease, asthma and rare genetic diseases. Dr. Monia's publication record exceeds 150 primary research manuscripts, reviews and book chapters and is an inventor on more than 100 issued patents. In addition, Dr. Monia serves on the editorial boards for a number of scientific journals, is a member of the American Association of Cancer Research, the American Diabetes Association, the American Association for the Study of Liver Diseases, the American Society of Hematology and serves on the Board of Directors for the Oligonucleotide Therapeutics Society. He also holds a position as a scientific advisory board member with OncoGeneX Technologies, Inc., and is an adjunct professor of biology at San Diego State University where he lectures at the graduate level on pharmacology. Mr. Monia received his Ph.D. in Pharmacology at the University of Pennsylvania and B.S. degrees in Molecular Biology and Analytical Chemistry at Stockton State College, in Pomona, New Jersey.

CEO Compensation
  • Brett's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Brett's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Ionis Pharmaceuticals management team in years:

4.8
Average Tenure
61
Average Age
  • The tenure for the Ionis Pharmaceuticals management team is about average.
Management Team

Stan Crooke

TITLE
Founder & Executive Chairman
COMPENSATION
$8M
AGE
74

Brett Monia

TITLE
Founder
COMPENSATION
$4M
AGE
58
TENURE
0.3 yrs

Elizabeth Hougen

TITLE
Senior VP of Finance & CFO
COMPENSATION
$3M
AGE
57
TENURE
7.3 yrs

Patrick O'Neil

TITLE
Senior VP of Legal
COMPENSATION
$3M
AGE
45
TENURE
7.3 yrs

B. Parshall

TITLE
Senior Strategic Advisor & Director
COMPENSATION
$6M
AGE
65
TENURE
2.3 yrs

Richard Geary

TITLE
Senior Vice President of Development
COMPENSATION
$3M
AGE
61
TENURE
11.7 yrs

Darren Gonzales

TITLE
Chief Accounting Officer
TENURE
0.2 yrs

C. Bennett

TITLE
Chief Scientific Officer
COMPENSATION
$959K
AGE
62
TENURE
0.3 yrs

D. Walke

TITLE
Vice President of Investor Relations
TENURE
7.8 yrs

Roslyn Patterson

TITLE
Vice President of Communications
Board of Directors Tenure

Average tenure and age of the Ionis Pharmaceuticals board of directors in years:

16.1
Average Tenure
66.5
Average Age
  • The average tenure for the Ionis Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Stan Crooke

TITLE
Founder & Executive Chairman
COMPENSATION
$8M
AGE
74
TENURE
29.2 yrs

Brett Monia

TITLE
Founder
COMPENSATION
$4M
AGE
58
TENURE
1.1 yrs

B. Parshall

TITLE
Senior Strategic Advisor & Director
COMPENSATION
$6M
AGE
65
TENURE
19.6 yrs

Joseph Wender

TITLE
Director
COMPENSATION
$662K
AGE
74
TENURE
26.3 yrs

Spencer Berthelsen

TITLE
Director
COMPENSATION
$663K
AGE
67
TENURE
17.9 yrs

Skip Klein

TITLE
Director
COMPENSATION
$635K
AGE
58
TENURE
14.3 yrs

Frederick Muto

TITLE
Director
COMPENSATION
$628K
AGE
66
TENURE
19.1 yrs

Breaux Castleman

TITLE
Director
COMPENSATION
$635K
AGE
79
TENURE
6.8 yrs

Joseph Loscalzo

TITLE
Director
COMPENSATION
$643K
AGE
68
TENURE
6.2 yrs

Peter Reikes

TITLE
Director
COMPENSATION
$1M
AGE
58
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Ionis Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ionis Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ISI News

Simply Wall St News

ISI Company Info

Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington’s diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Details
Name: Ionis Pharmaceuticals, Inc.
ISI
Exchange: DB
Founded: 1989
$6,721,392,724
139,219,800
Website: http://www.ionispharma.com
Address: Ionis Pharmaceuticals, Inc.
2855 Gazelle Court,
Carlsbad,
California, 92010,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS IONS Common Stock Nasdaq Global Select US USD 17. May 1991
DB ISI Common Stock Deutsche Boerse AG DE EUR 17. May 1991
LSE 0JDI Common Stock London Stock Exchange GB USD 17. May 1991
SWX IONS Common Stock SIX Swiss Exchange CH CHF 17. May 1991
BMV IONS * Common Stock Bolsa Mexicana de Valores MX MXN 17. May 1991
Number of employees
Current staff
Staff numbers
817
Ionis Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 00:01
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/07
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.